Desmopressin acetate following cardiopulmonary bypass: evaluation of coagulation parameters.

Brown MR, Swygert TH, Whitten CW, Hebeler R

Journal of cardiothoracic anesthesia1 Dec 1989Cited by 23 (Europe PMC)

PMID2521029DOI10.1016/s0888-6296(89)94790-xPepBankPUB-02521029

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In elective CABG, DDAVP and placebo showed no significant coagulation differences across reported times except postoperative PTT.
In plain wordsIn elective CABG, coagulation tests showed no significant differences between DDAVP and placebo except postoperative PTT.
Peptide
Desmopressin
Outcome
No significant changeCoagulation tests
Study
n = 20
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
No significant differences between the two groups were found at induction, postprotamine, post-"study infusion," or 2 hours postoperatively, with the exception of the postoperative PTT (31.1 +/- 3.2 v 36.5 +/- 5.9 seconds for DDAVP v placebo, P = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
During elective CABG, 20 patients received either DDAVP, 0.3 microgram/kg, intravenously, following heparin reversal after CPB, or a placebo infusion, in a randomized, double-blind fashion.
Report a problemFND-0252102901
02HumanRandomized controlled trialEfficacy outcome
In elective CABG, postoperative PTT was 31.1 +/- 3.2 seconds with DDAVP versus 36.5 +/- 5.9 with placebo (P = 0.03).
In plain wordsIn elective CABG, DDAVP reduced postoperative PTT compared with placebo.
Peptide
Desmopressin
Outcome
DecreasePostoperative PTT
Study
n = 20
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Measurements
Postoperative PTT
31.1 seconds
DDAVP group, +/- 3.2
Postoperative PTT
36.5 seconds
placebo group, +/- 5.9
p
0.03
DDAVP versus placebo, postoperative PTT
Source sentences
Summary
No significant differences between the two groups were found at induction, postprotamine, post-"study infusion," or 2 hours postoperatively, with the exception of the postoperative PTT (31.1 +/- 3.2 v 36.5 +/- 5.9 seconds for DDAVP v placebo, P = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
During elective CABG, 20 patients received either DDAVP, 0.3 microgram/kg, intravenously, following heparin reversal after CPB, or a placebo infusion, in a randomized, double-blind fashion.
Report a problemFND-0252102902
03HumanRandomized controlled trialEfficacy outcome
In elective CABG, intraoperative and postoperative blood product transfusions were similar with DDAVP and placebo at all reported intervals.
In plain wordsIn elective CABG, blood product transfusions were similar with DDAVP and placebo.
Peptide
Desmopressin
Outcome
No significant changeBlood product transfusions
Study
n = 20
Comparator
Placebo
Outcome group
Bleeding and clotting · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
Total blood products transfused intraoperatively, and in the first 8, 16, 24, or 48 postoperative hours, were also similar between the groups.
1 context sentence(design, population, supporting numbers)
Summary · context
During elective CABG, 20 patients received either DDAVP, 0.3 microgram/kg, intravenously, following heparin reversal after CPB, or a placebo infusion, in a randomized, double-blind fashion.
Report a problemFND-0252102903
04HumanRandomized controlled trialSafety outcome
In elective CABG, no manifestations of hypercoagulability occurred with DDAVP or placebo.
In plain wordsIn elective CABG, neither DDAVP nor placebo patients showed hypercoagulability.
Peptide
Desmopressin
Outcome
Not applicableHypercoagulability
Study
n = 20
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Source sentences
Summary
No manifestations of hypercoagulability were seen, but hypotension during the infusion was noted in four patients receiving DDAVP, and in none of the controls.
1 context sentence(design, population, supporting numbers)
Summary · context
During elective CABG, 20 patients received either DDAVP, 0.3 microgram/kg, intravenously, following heparin reversal after CPB, or a placebo infusion, in a randomized, double-blind fashion.
Report a problemFND-0252102904
05HumanRandomized controlled trialSafety outcome
In elective CABG, hypotension during infusion occurred in four DDAVP patients and no controls.
In plain wordsIn elective CABG, hypotension occurred during infusion in four DDAVP patients and no controls.
Peptide
Desmopressin
Outcome
IncreaseHypotension during infusion
Study
n = 20
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
0.3 microgram/kg · intravenousAs given in this study (human).
Measurements
Patients with hypotension during infusion
4 patients
DDAVP group
Source sentences
Summary
No manifestations of hypercoagulability were seen, but hypotension during the infusion was noted in four patients receiving DDAVP, and in none of the controls.
1 context sentence(design, population, supporting numbers)
Summary · context
During elective CABG, 20 patients received either DDAVP, 0.3 microgram/kg, intravenously, following heparin reversal after CPB, or a placebo infusion, in a randomized, double-blind fashion.
Report a problemFND-0252102905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07012837

Transfusion Reduction in High-Bleeding-Risk Cardiac Surgery With Desmopressin

Imam Abdulrahman Bin Faisal Universityn = 112est. Jul 2025 to est. Aug 2027

Adult Patients Undergoing Cardiac Surgery · High Bleeding Risks · Planned Elective Cardiac Surgery Using CPB

Trial page ClinicalTrials.govUpdated 10 Jun 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.